CD28: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of CD28. The page also collects GeneMedi's different modalities and formats products for CD28 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the CD28 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Transmembrane Protein.
The protein encoded by this gene is essential for T-cell proliferation and survival, cytokine production, and T-helper type-2 development. Several alternatively spliced transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, Jul 2011]
|Gene Official Name||CD28|
|Protein Sub-location||Transmembrane Protein|
|Category||Therapeutics Target, INN Index, Immuno-oncology Target|
Pre-made CD28-specific INN-index biosimilar (antibody&conjugates)-Lulizumab, acazicolcept, lulizumab pegol
Anti-CD28 therapeutic INN-index antibodies and conjugates are biosimilars expressed by mammalian cell line as a benchmark reference therapeutic antibody for drug discovery, target MOA research, cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
|Cat No.||Products Name (INN Index)||INN Name||Previous Name||Target||Format||Order|
|GMP-Bios-ab-326||Pre-Made Lulizumab biosimilar, Single Domain Variable Fragment;L, Anti-CD28 Antibody: Anti-Tp44 therapeutic antibody||Lulizumab||CD28||Single Domain Variable Fragment;L|
|GMP-Bios-INN-715||Pre-Made Acazicolcept Biosimilar, Fusion Protein targeting CD28 fused with human IGHG1 Fc (Fragment constant) via a peptidyl linker: Recombinant therapeutic protein targeting Tp44||acazicolcept||CD28||Fusion Protein|
Pre-made anti-CD28 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark reference antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-CD28 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-CD28 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
|Cat No.||Antibody Name||Format||Classified by tag||Order|
|GM-Tg-hg-T85529-Ab||Anti-CD28 monoclonal antibody||mab||Biofunctional antibody, Therapeutics Target antibody|